Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Oncology Practice

• Publication date

  2017-04-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JOP.2016.020206PMID 28628393PMCID PMC5555032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physician's peer exposure and the adoption of a new cancer treatment modality

  2015cited by this paper
• Factors affecting the uptake of new medicines: a systematic literature review

  2014cited by this paper
• Enzalutamide in metastatic prostate cancer before chemotherapy.

  2014cited by this paper
• Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

  2014cited by this paper
• Understanding regional variation in the use of surgery

  2014cited by this paper
• Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Castration-resistant prostate cancer: AUA Guideline.

  2013cited by this paper
• Surgical skill and complication rates after bariatric surgery.

  2013cited by this paper
• Re: Abiraterone in metastatic prostate cancer without previous chemotherapy.

  2013cited by this paper
• Geographic variation in outpatient antibiotic prescribing among older adults.

  2012cited by this paper
• Prostate cancer epidemiology in the United States

  2012cited by this paper
• Geographic Variation in the Surgical Treatment of Degenerative Cervical Disc Disease: American Board of Orthopedic Surgery Quality Improvement Initiative; Part II Candidates

  2012cited by this paper
• Disparities in the Early Adoption of Chemoimmunotherapy for Diffuse Large B-cell Lymphoma in the United States

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• Increased survival with enzalutamide in prostate cancer after chemotherapy.

  2012cited by this paper
• Abiraterone and increased survival in metastatic prostate cancer.

  2011cited by this paper
• NCCN clinical practice guidelines in oncology: prostate cancer.

  2010cited by this paper
• Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review.

  2009cited by this paper
• Variation in hospital mortality associated with inpatient surgery.

  2009cited by this paper
• Potentially Avoidable Hospitalizations for COPD and Pneumonia: The Role of Physician and Practice Characteristics

  2007cited by this paper
• General practitioners' adoption of new drugs and previous prescribing of drugs belonging to the same therapeutic class: a pharmacoepidemiological study.

  2005cited by this paper
• Impact of clinical trials on the adoption of new drugs within a university hospital

  2004cited by this paper
• Trends and geographic variations in major surgery for degenerative diseases of the hip, knee, and spine.

  2004cited by this paper
• Who you are and where you live: how race and geography affect the treatment of medicare beneficiaries.

  2004cited by this paper
• Geography and the debate over Medicare reform.

  2002cited by this paper
• The Siege of Mafeking from a medical point of view

  2001cited by this paper
• Successes and Failures in the Implementation of Evidence-Based Guidelines for Clinical Practice

  2001cited by this paper
• Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care.

  2000cited by this paper
• Variation in the use of laparoscopic cholecystectomy for elderly patients with acute cholecystitis.

  2000cited by this paper
• Why don't physicians follow clinical practice guidelines? A framework for improvement.

  1999cited by this paper
• Variation profiles of common surgical procedures.

  1998cited by this paper
• Do physicians do what they say? The inclination to test and its association with coronary angiography rates.

  1997cited by this paper
• Do Physicians Do What They Say?: The Inclination to Test and Its Association with Coronary Angiography Rates

  1997cited by this paper
• The association between local diagnostic testing intensity and invasive cardiac procedures.

  1996cited by this paper
• Variations in physician practice: the role of uncertainty.

  1984cited by this paper

• Hormonal Therapy Patterns in Older Men with Prostate Cancer in the United States, 2010–2019

  2025cites this paper
• Patterns of Care for Medicare Beneficiaries With Metastatic Prostate Cancer

  2024cites this paper
• In-office dispensing of oral targeted agents by urology practices in men with advanced prostate cancer

  2023cites this paper
• Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

  2022cites this paper
• Understanding Prescribing Differences Between Urologists and Medical Oncologists in the Management of Advanced Prostate Cancer

  2022cites this paper
• Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial

  2021cites this paper
• Adoption of Abiraterone and Enzalutamide by Urologists.

  2019cites this paper
• Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

  2018cites this paper
• Temporal and geographic variation in the systemic treatment of advanced prostate cancer

  2018influential citation